溃疡性结肠炎
医学
移植
粪便细菌疗法
结肠炎
内科学
免疫学
胃肠病学
微生物学
生物
抗生素
疾病
艰难梭菌
作者
Ajit Sood,Ramit Mahajan,Arshdeep Singh,Vandana Midha,Varun Mehta,Vikram Narang,Tarundeep Singh,Anmol Singh Pannu
出处
期刊:Journal of Crohn's and Colitis
[Oxford University Press]
日期:2019-03-09
卷期号:13 (10): 1311-1317
被引量:128
标识
DOI:10.1093/ecco-jcc/jjz060
摘要
To study the role of faecal microbiota transplantation [FMT] in maintenance of remission in ulcerative colitis [UC].In this pilot study, patients with UC in clinical remission achieved after multi-session FMT were randomly allocated to either maintenance FMT or placebo colonoscopic infusion every 8 weeks, for 48 weeks. The standard of care [SOC] therapy was continued in all patients. The primary endpoint was maintenance of steroid-free clinical remission [Mayo score ≤2, all subscores ≤1] at Week 48. Secondary endpoints were achievement of endoscopic remission [endoscopic Mayo score 0] and histological remission [Nancy grade 0, 1] at Week 48.In all, 61 patients in clinical remission were randomised to receive either FMT [n = 31] or placebo [n = 30]. The primary outcome was achieved in 27/31 [87.1%] patients allocated FMT versus 20/30 [66.7%] patients assigned placebo [p = 0.111]. Secondary endpoints of endoscopic remission (FMT: 18/31 [58.1%] versus placebo: 8/30 [26.7%], p = 0.026) and histological remission (FMT: 14/31 [45.2%] versus placebo: 5/30 [16.7%], p = 0. 033) were achieved in a significantly higher number of patients with FMT. Three patients receiving FMT [9.7%] and 8 patients on placebo [26.7%] relapsed. There were no serious adverse events necessitating discontinuation in patients on FMT; one patient who relapsed on placebo required colectomy.Maintenance FMT in patients who are in clinical remission may help sustain clinical, endoscopic and histological remission in patients with UC.
科研通智能强力驱动
Strongly Powered by AbleSci AI